Serum WFA+-M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C-Reference-Cited by-同舟云学术

Serum WFA+-M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C

Published:2015-10-26 Issue:1 Volume:43 Page:114-124
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Ura K.¹²,Furusyo N.¹²,Ogawa E.¹²,Hayashi T.¹,Mukae H.¹,Shimizu M.¹,Toyoda K.¹,Murata M.¹²,Hayashi J.³

Affiliation:

1. Department of General Internal Medicine; Kyushu University Hospital; Fukuoka Japan

2. Department of Environmental Medicine and Infectious Disease; Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan

3. Kyushu General Internal Medicine Center; Haradoi Hospital; Fukuoka Japan

Funder

Sysmex Co

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.13431/fullpdf

Reference33 articles.

1. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence;Mohd;Hepatology,2013

2. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C;Poynard;J Hepatol,2013

3. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study;Ogawa;J Hepatol,2013

4. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C;Rutter;Aliment Pharmacol Ther,2015

5. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C;Furusyo;J Hepatol,2013

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarcadores séricos para la evaluación de la fibrosis hepática;Advances in Laboratory Medicine / Avances en Medicina de Laboratorio;2024-02-14

2. Serum biomarkers for liver fibrosis assessment;Advances in Laboratory Medicine / Avances en Medicina de Laboratorio;2023-11-14

3. Serum inducible protein 10 kDa/C‐X‐C motif chemokine 10 levels predict regression of M2BPGi‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents;Hepatology Research;2023-09-06

4. Real-world efficacy and safety of glecaprevir/pibrentasvir in Japanese adolescents with chronic hepatitis C: a prospective multicenter study;Journal of Gastroenterology;2023-02-15

5. Serum Mac-2 Binding Protein Glycosylation Isomer to Predict the Severity of Hepatic Fibrosis in Patients with Hepatitis C Virus Infection;Diagnostics;2022-10-31